Kontafarma China Holdings Ltd (HK:1312)
:1312
Want to see HK:1312 full AI Analyst Report?
Top Page
Kontafarma China Holdings Ltd
(1312)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$0.03
▼(-6.67% Downside)
Action:Reiterated
Date:05/01/26
The score is driven primarily by weak operating profitability and sharply wider 2025 losses, which outweigh positives in cash generation and improving leverage. Technicals are broadly neutral and do not provide a strong offset, while valuation metrics are constrained by negative earnings and no dividend yield.
Positive Factors
High gross margins
Sustained gross margins near 50%+ indicate durable pricing power or a favorable product mix. That gross-level resilience provides a structural buffer against input-cost swings and gives management scope to restore operating profitability through SG&A or scale efficiencies over the medium term.
Negative Factors
Negative operating profitability
Sustained negative EBIT/EBITDA signals core operations are loss-making and that gross margin strength hasn’t translated to operating profit. Without structural cost reduction or better operating leverage, continued operating losses will pressure cash flow conversion and long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained gross margins near 50%+ indicate durable pricing power or a favorable product mix. That gross-level resilience provides a structural buffer against input-cost swings and gives management scope to restore operating profitability through SG&A or scale efficiencies over the medium term.
Read all positive factors
Kontafarma China Holdings Ltd (1312) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$167.36M
Dividend YieldN/A
Average Volume (3M)9.95M
Price to Earnings (P/E)―
Beta (1Y)0.17
Revenue Growth1.92%
EPS Growth-468.15%
CountryHK
Employees714
SectorHealthcare
Sector Strength45
IndustryConstruction Materials
Share Statistics
EPS (TTM)-0.08
Shares Outstanding5,588,572,000
10 Day Avg. Volume1,701,000
30 Day Avg. Volume9,954,100
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.18
P/FCF Ratio3.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kontafarma China Holdings Ltd Business Overview & Revenue Model
Company Description
Kontafarma China Holdings Ltd. engages in the manufacture and sale of cement. It operates through the following segments: Pharmaceutical and Fitness Business. The Pharmaceutical Business segment involves in manufacture and sales of prescription dr...
Kontafarma China Holdings Ltd Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
46
Neutral
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 914.71M | 897.52M | 809.11M | 894.06M | 803.27M |
| Gross Profit | 513.64M | 516.16M | 471.29M | 506.22M | 396.18M |
| EBITDA | -14.32M | -49.93M | 78.50M | 26.93M | 112.18M |
| Net Income | -427.85M | -75.54M | -28.84M | -41.55M | -15.05M |
Balance Sheet | |||||
| Total Assets | 1.07B | 1.59B | 1.73B | 2.12B | 2.56B |
| Cash, Cash Equivalents and Short-Term Investments | 66.06M | 90.58M | 87.66M | 142.59M | 183.96M |
| Total Debt | 203.68M | 297.19M | 333.82M | 590.72M | 728.95M |
| Total Liabilities | 588.92M | 625.90M | 665.39M | 964.16M | 1.22B |
| Stockholders Equity | 553.26M | 978.70M | 1.06B | 1.10B | 1.19B |
Cash Flow | |||||
| Free Cash Flow | 53.15M | 33.41M | 12.92M | -53.84M | -49.31M |
| Operating Cash Flow | 76.68M | 47.05M | 37.12M | -2.17M | 75.07M |
| Investing Cash Flow | 8.82M | -6.01M | 144.14M | 121.53M | 23.24M |
| Financing Cash Flow | -90.16M | -42.52M | -198.81M | -137.33M | -99.80M |
Kontafarma China Holdings Ltd Technical Analysis
Negative
0.03
Price Trends
0.03
Negative
0.03
Positive
0.03
Negative
Market Momentum
>-0.01
Negative
46.74
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1312, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.74 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1312.
Kontafarma China Holdings Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | HK$45.08B | 11.93 | 7.86% | 2.65% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$739.99M | 2.64 | 2.06% | ― | 0.18% | ― | |
47 Neutral | HK$37.74B | -1.29 | -2.95% | 3.30% | -2.13% | -279.50% | |
45 Neutral | HK$167.36M | -0.38 | -69.10% | ― | 1.92% | -468.15% | |
44 Neutral | HK$69.62M | -1.33 | -8.97% | ― | 63.58% | -38.19% | |
42 Neutral | HK$749.48M | -0.05 | 211.43% | ― | -11.62% | -138.95% |
* Healthcare Sector Average
HK:1312
Kontafarma China Holdings Ltd
0.03
<0.01
3.45%
HK:3323
China National Building Material Co
4.97
1.49
42.90%
HK:0868
Xinyi Glass Holdings
10.19
2.74
36.80%
HK:3300
China Glass Holdings Limited
0.45
0.21
85.42%
HK:1252
China Tianrui Group Cement Co., Ltd.
0.24
-0.03
-11.11%
HK:1847
YCIH Green High-Performance Concrete Co., Ltd. Class H
0.52
0.11
26.83%
Kontafarma China Holdings Ltd Corporate Events
Kontafarma China Sets 2026 AGM, Seeks Fresh Share Issuance Mandate
Apr 23, 2026
Kontafarma China Holdings has called its annual general meeting for 5 June 2026 in Hong Kong, where shareholders will be asked to receive and adopt the audited financial statements for the year ended 31 December 2025. The agenda also includes re-e...
Kontafarma China Moves to Update Articles and Enable Treasury Shares Ahead of 2026 AGM
Apr 20, 2026
Kontafarma China Holdings plans to adopt a fourth amended and restated memorandum and articles of association to align its constitutional documents with updated Hong Kong legal and regulatory requirements on electronic dissemination of corporate c...
Kontafarma China announces board reshuffle with new executive director and vice president
Apr 16, 2026
Kontafarma China Holdings Ltd announced that executive director Liu Jiankun has resigned effective 16 April 2026 to pursue other work commitments, and will also step down from the company’s executive committee and share dealing committee. Th...
Kontafarma China Overhauls Board and Committee Structure
Apr 16, 2026
Kontafarma China Holdings Ltd has reshuffled its board structure with effect from 16 April 2026, confirming Wang Feifei as chairman and president alongside two other executive directors, one non-executive director and three independent non-executi...
Kontafarma China’s 2025 Loss Widens Sharply Despite Stable Revenue
Mar 27, 2026
Kontafarma China Holdings reported audited revenue of HK$914.7 million for 2025, slightly up from HK$897.5 million a year earlier, but gross profit remained broadly flat at HK$513.6 million. The group’s cost of sales, distribution, and admin...
Kontafarma China Sets March Board Meeting to Approve 2025 Results
Mar 16, 2026
Kontafarma China Holdings Limited has scheduled a board meeting for 27 March 2026 to review and approve the audited annual results for the year ended 31 December 2025. The board will also deliberate on the potential declaration of a final dividend...
Kontafarma Flags Deepened 2025 Loss on Major Fitness Impairments
Mar 11, 2026
Kontafarma China Holdings has warned that it expects to report a sharply wider consolidated net loss of about HK$414.1 million to HK$506.2 million for 2025, compared with a HK$99 million loss a year earlier. The deterioration is driven mainly by h...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.